JP2021529780A5 - - Google Patents
Info
- Publication number
- JP2021529780A5 JP2021529780A5 JP2020573365A JP2020573365A JP2021529780A5 JP 2021529780 A5 JP2021529780 A5 JP 2021529780A5 JP 2020573365 A JP2020573365 A JP 2020573365A JP 2020573365 A JP2020573365 A JP 2020573365A JP 2021529780 A5 JP2021529780 A5 JP 2021529780A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- syndrome
- disease
- aryl
- autoimmune
- Prior art date
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693879P | 2018-07-03 | 2018-07-03 | |
| US201862693886P | 2018-07-03 | 2018-07-03 | |
| US62/693,879 | 2018-07-03 | ||
| US62/693,886 | 2018-07-03 | ||
| US201862702602P | 2018-07-24 | 2018-07-24 | |
| US201862702621P | 2018-07-24 | 2018-07-24 | |
| US62/702,621 | 2018-07-24 | ||
| US62/702,602 | 2018-07-24 | ||
| PCT/US2019/040357 WO2020010118A1 (en) | 2018-07-03 | 2019-07-02 | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529780A JP2021529780A (ja) | 2021-11-04 |
| JP2021529780A5 true JP2021529780A5 (https=) | 2022-07-11 |
| JPWO2020010118A5 JPWO2020010118A5 (https=) | 2022-07-11 |
Family
ID=67441657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573365A Pending JP2021529780A (ja) | 2018-07-03 | 2019-07-02 | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220339169A1 (https=) |
| EP (1) | EP3817737A1 (https=) |
| JP (1) | JP2021529780A (https=) |
| KR (1) | KR20210030947A (https=) |
| CN (1) | CN112654350A (https=) |
| AU (1) | AU2019299444A1 (https=) |
| CA (1) | CA3103664A1 (https=) |
| IL (1) | IL279889A (https=) |
| WO (1) | WO2020010118A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| JP7349981B2 (ja) * | 2017-07-24 | 2023-09-25 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US11530200B2 (en) | 2018-03-02 | 2022-12-20 | Inflazome Limited | Compounds |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CR20210024A (es) | 2018-07-20 | 2021-02-22 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| JP7392169B2 (ja) * | 2019-11-12 | 2023-12-05 | 成都百裕制薬股▲ふん▼有限公司 | アミド誘導体及びその調製方法並びに医薬における応用 |
| ES2991366T3 (es) | 2020-05-08 | 2024-12-03 | Halia Therapeutics Inc | Inhibidores de NEK7 cinasa |
| WO2022047758A1 (en) * | 2020-09-05 | 2022-03-10 | Zhejiang University | Genetical disease modelling using mammals having nlrp3 mutation |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN116917282A (zh) * | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| US20250082611A1 (en) * | 2021-07-23 | 2025-03-13 | Novartis Ag | Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis |
| JP2024532476A (ja) * | 2021-09-02 | 2024-09-05 | モレキュラー アクシオム エルエルシー | Ｎｌｒｐ３またはｎｌｒｐ１発現を調節するための組成物及び方法 |
| CN118302415A (zh) * | 2021-12-03 | 2024-07-05 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的制备方法 |
| US20230416412A1 (en) * | 2022-05-31 | 2023-12-28 | Hoffmann-La Roche Inc. | Prevention or mitigation of t-cell engaging agent-related adverse effects |
| EP4561574A1 (en) * | 2022-07-27 | 2025-06-04 | Novartis AG | Dosing regimen for a nlrp3 inhibitor |
| CN116459260A (zh) | 2023-04-28 | 2023-07-21 | 中国人民解放军空军军医大学 | 一种特异性靶向nlrp3炎症小体抑制剂的用途 |
| WO2024248287A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물 |
| WO2024248286A1 (ko) * | 2023-06-01 | 2024-12-05 | 한양대학교 에리카산학협력단 | 결핵균 유래 폴리펩타이드를 포함하는 암 치료용 약학 조성물 |
| WO2025068958A1 (en) * | 2023-09-29 | 2025-04-03 | Novartis Ag | Nlrp3 inhibitor for use in lowering the risk of cardiovascular diseases |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| AU630497B2 (en) | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
| ZA929699B (en) * | 1991-12-20 | 1994-06-14 | Lilly Co Eli | Sulfonimidamides |
| KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
| US5705398A (en) | 1994-03-02 | 1998-01-06 | The Scripps Research Institute | Methods for identifying inhibitors of LPS-mediated LBP binding |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| JP2005510542A (ja) * | 2001-11-30 | 2005-04-21 | ファイザー・プロダクツ・インク | 炎症の治療のための、ｉｌ−１／１８阻害剤及びｔｎｆ阻害剤の組み合わせ。 |
| US7749999B2 (en) * | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| WO2006133286A2 (en) * | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US8884006B2 (en) | 2011-09-19 | 2014-11-11 | University Of Puerto Rico | Small-molecule inhibitors of Rac1 in metastatic breast cancer |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| US20180008629A1 (en) * | 2015-01-29 | 2018-01-11 | Yale University | Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders |
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| WO2017079352A2 (en) * | 2015-11-04 | 2017-05-11 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting nlrp3 gene expression and uses thereof |
| WO2017123672A1 (en) * | 2016-01-12 | 2017-07-20 | Lawrence Chan | Combination treatment for inflammatory diseases |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| US11339136B2 (en) * | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| NZ760129A (en) * | 2017-07-07 | 2025-12-19 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| ES2988798T3 (es) * | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| JP7349981B2 (ja) * | 2017-07-24 | 2023-09-25 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| WO2019166624A1 (en) * | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
-
2019
- 2019-07-02 AU AU2019299444A patent/AU2019299444A1/en not_active Abandoned
- 2019-07-02 EP EP19745415.0A patent/EP3817737A1/en not_active Withdrawn
- 2019-07-02 US US17/252,630 patent/US20220339169A1/en not_active Abandoned
- 2019-07-02 WO PCT/US2019/040357 patent/WO2020010118A1/en not_active Ceased
- 2019-07-02 KR KR1020217003092A patent/KR20210030947A/ko not_active Withdrawn
- 2019-07-02 CN CN201980052145.7A patent/CN112654350A/zh active Pending
- 2019-07-02 JP JP2020573365A patent/JP2021529780A/ja active Pending
- 2019-07-02 CA CA3103664A patent/CA3103664A1/en not_active Abandoned
-
2020
- 2020-12-30 IL IL279889A patent/IL279889A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529780A5 (https=) | ||
| JP7551060B2 (ja) | プログラム可能なポリマー薬 | |
| JP7603918B2 (ja) | プログラム可能なポリマー薬 | |
| CN116583508B (zh) | 一系列哌啶取代的苯酸类化合物及其应用 | |
| JP7618137B2 (ja) | プログラム可能なポリマー薬 | |
| JPWO2020010118A5 (https=) | ||
| KR102793563B1 (ko) | 악성 종양 치료용 제제 및 조성물 | |
| CA3103664A1 (en) | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist | |
| US12486278B2 (en) | MASP-2 inhibitors and methods of use | |
| JP6920202B2 (ja) | Ｉｒａｋ阻害剤としてのピリダジノン大環状化合物及びその使用 | |
| JP7721142B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| US12110288B2 (en) | MASP-2 inhibitors and methods of use | |
| AU2023266363A1 (en) | MASP-2 inhibitors and methods of use | |
| JP2019506380A5 (https=) | ||
| AU2013351622A1 (en) | Heteroaryl alkyne compound and application thereof | |
| AU2013227024A1 (en) | Novel piperidine compound or salt thereof | |
| JP7058322B2 (ja) | 細菌感染症を治療するための化合物および方法 | |
| JP2025521156A (ja) | Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用 | |
| US20240336606A1 (en) | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof | |
| KR20170005868A (ko) | S100-저해제로서 유용한 새로운 화합물 | |
| JP7731151B2 (ja) | トリアゾロピラジン系化合物及びその用途 | |
| US20250263383A1 (en) | Novel inhibitors of guanosine monophosphate synthetase as therapeutic agents | |
| WO2025166260A1 (en) | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors | |
| WO2016050201A1 (zh) | 高选择性取代嘧啶类pi3k抑制剂 | |
| WO2018187509A1 (en) | Heterocyclic compounds as chemokine receptor modulators |